Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact

Breaking Down Silos. Connecting Expertise. Accelerating Patient Impact.

Biomarkers & CDx Program at Precision Medicine East


, ,

The Biomarkers & CDx program covers the path from biomarker discovery and validation to companion diagnostics that reach patients. It is for translational and clinical biomarker leads, CDx developers, and regulatory and market access teams.

Session Themes

Which biomarkers will reach patients, and what will it take to get them approved and paid for? Sessions follow the biomarker from early evidence to clinical use, alongside the diagnostics, data and regulatory decisions it depends on. Session themes include:

Biomarkers in Translational & Clinical Development
How biomarkers are identified, validated and applied to guide patient stratification, treatment selection and personalized therapeutic strategies.

Tools & Technologies for Biomarker Analysis
How liquid biopsies, genomic tools and other emerging technologies are improving biomarker detection, analysis and interpretation.

Biomarkers for Clinical Trials & Personalized Patient Treatment
Using biomarkers to design better trials, stratify patients and predict treatment response.

Companion Diagnostics & Regulations
How companion diagnostics are developed, validated and regulated to support targeted therapies.

Featured Sessions

IVDR Regulations & Their Impact (panel) · AI-Enabled Clinical Trial Innovation: From Biomarker Data to Decisions (panel) · Proteomic Innovations to Drive Discovery · The Future of Liquid Biopsy: Emerging Technologies, Clinical Translation & Cross-Sector Collaboration

Biomarkers & CDx in Boston

New to Boston in 2027, the Biomarkers & CDx program at Precision Medicine East draws on some of America’s longest-standing academic medical centers and biopharma institutions, with clinical research at its core.

Few places bring the whole biomarker journey this close together. Discovery labs, translational teams, diagnostics developers and the hospitals that run clinical trials all sit within a short distance of each other. That makes Boston a natural home for a program focused on turning biomarkers into companion diagnostics that reach patients.

The program also meets one of the strongest omics and spatial biology communities in the US, built over years of NextGen Omics, Spatial & Data US. Biomarker and CDx leaders can now work directly with the scientists generating the molecular and spatial data behind their next assay.

Boston Skyline

The questions shaping biomarkers in 2027

Biomarkers & CDx is new to Boston for 2027, joining the omics and spatial biology community that has long met there. It brings the people who define biomarker strategy into the same room as the scientists generating the molecular and spatial data behind it.

Liquid biopsies, AI-driven discovery and spatial and multi-omics profiling are creating new opportunities for biomarker discovery, patient stratification and treatment selection. Translating these advances into drug development, companion diagnostics and clinical practice requires robust validation, reproducible results and clear evidence of clinical utility.

At Precision Medicine East, the program runs alongside Computational Pathology, AI & Precision Diagnostics; Multi-Omics Development & Applications; and AI, Data & Analysis, so you can trace a biomarker from the first molecular signal to the diagnostic that reaches patients.

Who should attend

Translational and clinical biomarker leads

CDx developers 

Regulatory and market access teams 

Diagnostics companies 

Clinicians

Clinical trial experts 

Biomarker analysis teams

Biomarkers CDx Who Should Attend Image-2

Featured Speakers for Precision Medicine East Biomarkers & CDx

Giorgio Gaglia
Senior Principal Scientist,
Sanofi
Iulian Pruteanu-Malinici
Senior Director Bioinformatics,
Flagship Pioneering/Pioneering Medicines
Marla Weetall
Sr. Vice President, Pharmacology and Biomarkers,
PTC Therapeutics
Minakshi Guha
Associate Director, LBx Strategy, PSI, Oncology Precision & Translational Medicine,,
Takeda
Preeyam Patel
Director, Translational Sciences,
Spyre Therapeutics
Premi Haynes
Principal Scientist,
Bristol Myers Squibb
Rajib Schubert
Professor,
KAIST
Russell LaMontagne
Chief Executive Officer,
Boston Immune Technologies and Therapeutics, Inc.
Simone Filosto
director,
Kite, A Gilead Company
Tara Dutka
Program Director of All of Us Genome Centers,
National Institutes of Health
Vasundhara Pathak
Director, Global Regulatory Affairs / Global Regulatory Lead, Oncology,
CRUK AstraZeneca Antibody Alliance Laboratory
Yeoun-Jin Kim
Senior Director and Head of Translational Proteomics,
AstraZeneca

Biomarkers & CDx Speakers

How it connects

Biomarkers & CDx focuses on clinical translation and treatment-linked diagnostic testing. It works hand in hand with the other three programs: new biomarker candidates from omics, pathology and data science need validated tests before they can inform clinical decisions. 

Frequently Asked Questions

Which biomarkers will reach patients, and what will it take?
The program puts patient impact at the center, with a dedicated track on Biomarkers for Clinical Trials & Personalized Patient Treatment. Sessions cover how to identify clinically actionable biomarkers, test their effectiveness and turn promising discoveries into clinical decisions. 
How are IVDR regulations shaping precision medicine?
The Companion Diagnostics & Regulations track looks at how IVDR is shaping companion diagnostic development, clinical trial requirements and implementation, covering compliance, assay validation and NGS-based companion diagnostics. The panel IVDR Regulations & Their Impact discusses what comes next. 
Which technologies will have the biggest impact on biomarker analysis?
Sessions span genomics, single-cell and spatial technologies, proteomics, mass spectrometry, flow cytometry and metabolomics, with dedicated discussions on proteomics and the future of liquid biopsy, and on how AI and machine learning strengthen discovery and patient stratification. 
Who should attend the Biomarkers & CDx program?

Translational and clinical biomarker leads, CDx developers, regulatory and market access teams, diagnostics companies, clinicians, clinical trial experts and biomarker analysis teams. 

When and where is the Biomarkers & CDx program at Precision Medicine East?
March 23–24, 2027, at the Sheraton Boston Hotel. Session times will be on the agenda. 

Be part of the conversations shaping
the future of medicine.


, ,

Spatial Multi-Omics 2026 Agenda at a Glance

DAY ONE 

Track 2: Emerging Multi-Omics Platforms and Applications: Genomics & Transcriptomics 
Track 3: Spatial Biology for Therapeutic Discovery & Development (Oncology & Immunology) 

DAY TWO 

Track 1: Emerging Multi-Omics Platforms and Applications: Proteomics, Epigenomics & Metabolomics 
Track 2: Spatial Biology for Therapeutic Discovery & Development
NGOUS Conference Brochure

Decision 1

Sentence describing Decision 1

Decision 2

Sentence describing Decision 2